Fake fiancée! It was Mike Black's job to keep Candee safe until she testified in court. But his idea of protection meant hiding out with her at his brother's ranch and pretending she was his fiancée! Candee was not impressed—she was a city girl, and confinement in the country was not her idea of fun. The only compensation was living with Mike, but he knew better than to get involved with an irresistible, bubbly blonde. Past experience had taught him it could only lead to one thing: trouble!

Clinical trials provide essential information needed to turn basic medical research findings into patient treatments. New treatments must be studied in large numbers of humans to find out whether they are effective and to assess any harm that may arise from treatment. There is growing recognition among many stakeholders that the U.S. clinical trials enterprise is unable to keep pace with the national demand for research results. The IOM, along with the Mount Sinai School of Medicine, held a workshop June 27-28, 2011, to engage stakeholders and experts in a discussion about possible solutions to improve public engagement in clinical trials.

Public Diplomacy is now one of the most important concepts in the development and implementation of foreign policy. Trials of Engagement: The Future of US Diplomacy analyses the trials of contemporary practice and identifies factors which will shape a more collaborative future of public diplomacy.

On March 3-4, 2016, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop in Washington, DC, bringing together key stakeholders to discuss opportunities for improving the integrity, efficiency, and validity of clinical trials for nervous system disorders. Participants in the workshop represented a range of diverse perspectives, including individuals not normally associated with traditional clinical trials. The purpose of this workshop was to generate discussion about not only what is feasible now, but what may be possible with the implementation of cutting-edge technologies in the future.

Successful drug development relies on accurate and efficient clinical trials to deliver the best and most effective pharmaceuticals and clinical care to patients. However, the current model for clinical trials is outdated, inefficient and costly. Clinical trials are limited by small sample sizes that do not reflect variations among patients in the real world, financial burdens on participants, and slow processes, and these factors contribute to the disconnect between clinical research and clinical practice. On November 28-29, the National Academies of Sciences, Engineering, and Medicine convened a workshop to investigate the current clinical trials system and explore the potential benefits and challenges of implementing virtual clinical trials as an enhanced alternative for the future. This publication summarizes the presentations and discussions from the workshop.

Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients.

Volume contains: (Lincoln Square Center, Inc. v. St. Nicholas Arena, Inc.) (Lincoln Square Center, Inc. v. St. Nicholas Arena, Inc.) (Lincoln Square Center, Inc. v. St. Nicholas Arena, Inc.) (Lincoln Square Center, Inc. v. St. Nicholas Arena, Inc.) (L.O.L. Productions Inc. v. Soundies Distributing Corp. of America, Inc.) (L.O.L. Productions Inc. v. Soundies Distributing Corp. of America, Inc.) (L.O.L. Productions Inc. v. Soundies Distributing Corp. of America, Inc.) (L.O.L. Productions Inc. v. Soundies Distributing Corp. of America, Inc.) (McKesson & Robbins, Inc. v. Caballero) (McKesson & Robbins, Inc. v. Caballero) (McKesson & Robbins, Inc. v. Caballero) (Manhattan Savings Bank v. Tuttle) (Manhattan Savings Bank v. Tuttle) (Manhattan Savings Bank v. Tuttle) (Manhattan Savings Bank v. Tuttle) (Matter of Marx) (Matter of Marx) (Matter of Marx) (Melioris v. Morgenstern) (Melioris v. Morgenstern) (Melioris v. Morgenstern)